{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:18:54Z","timestamp":1791195534929,"version":"4.1.0"},"reference-count":70,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,29]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>\u201cNonclassical\u201d myeloproliferative neoplasms (MPNs) and myelodysplastic\/myeloproliferative neoplasms (MDS\/MPNs) represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. Unlike classical MPNs, there is no standardized management approach for these conditions, particularly concerning the indications for and management of allogeneic hematopoietic cell transplantation. To address this gap, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&amp;G) Committee and the Chronic Malignancies Working Party (CMWP) have collaborated to develop shared guidelines aimed at optimizing the selection and management of patients with these rare forms of neoplasms. A comprehensive review of the literature from the publication of the revised fourth edition of the (2016) World Health Organization classification onward was conducted. A multidisciplinary group of experts in the field convened to produce this document, which was developed through multiple rounds of draft circulation. Key recommendations include the early identification of potential transplant candidates, particularly in cases of chronic neutrophilic leukemia, chronic eosinophilic leukemia (CEL)\/CEL, not otherwise specified (CEL-NOS), myeloid\/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions with FGFR1, JAK2, ABL1, and FLT3 rearrangements, MDS\/MPN with neutrophilia\/atypical chronic myeloid leukemia, and MDS\/MPN, NOS. For patients with MPN, NOS\/MPN unclassifiable, standard recommendations for myelofibrosis should be applied. Similarly, in MDS\/MPN with thrombocytosis, transplantation is recommended on the basis of established MDS guidelines. Given the current lack of robust evidence, this document will serve as a valuable resource to guide future research activities, providing a framework for addressing critical unanswered questions and advancing the field.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024028000","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T20:04:38Z","timestamp":1742414678000},"page":"2561-2573","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Role of allo-HCT in \u201cnonclassical\u201d MPNs and MDS\/MPNs: recommendations from the PH&amp;G Committee and the CMWP of the EBMT"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-9697","authenticated-orcid":false,"given":"Nicola","family":"Polverelli","sequence":"first","affiliation":[{"name":"1Unit of Bone Marrow Transplantation and Cellular Therapies, Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"Juan Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[{"name":"2Hospital Cl\u00ednico Universitario, Universidad de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[{"name":"3Practice Harmonisation and Guidelines Committee of the European Society for Blood and Marrow Transplantation, Hematology and Bone Marrow Transplantation Unit, Azienda Socio Sanitaria Territoriale Fatebenefratelli-Sacco, Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[{"name":"4Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"},{"name":"5Department of Translational Hematology and Oncology Research, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8258-354X","authenticated-orcid":false,"given":"Kavita","family":"Raj","sequence":"additional","affiliation":[{"name":"6Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3108-4035","authenticated-orcid":false,"given":"Tomasz","family":"Czerw","sequence":"additional","affiliation":[{"name":"7Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1859-6178","authenticated-orcid":false,"given":"Michelle","family":"Kenyon","sequence":"additional","affiliation":[{"name":"8Department of Haematology, King's College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-9876","authenticated-orcid":false,"given":"Marie","family":"Robin","sequence":"additional","affiliation":[{"name":"9H\u00f4pital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 de Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Sockel","sequence":"additional","affiliation":[{"name":"10Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"11Practice Harmonisation and Guidelines Committee of European Society for Blood and Marrow Transplantation and Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation, Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5519-9154","authenticated-orcid":false,"given":"Isabel","family":"S\u00e1nchez-Ortega","sequence":"additional","affiliation":[{"name":"12Practice Harmonisation and Guidelines Committee of European Society for Blood and Marrow Transplantation, Executive Office, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2160-9689","authenticated-orcid":false,"given":"Daniel A.","family":"Arber","sequence":"additional","affiliation":[{"name":"13Department of Pathology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[{"name":"1Unit of Bone Marrow Transplantation and Cellular Therapies, Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy"},{"name":"14Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Barroso","family":"Duarte","sequence":"additional","affiliation":[{"name":"15Hospital Universitario Walter Cant\u00eddio, Universidade Federal do Ceara, Fortaleza, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5201-1786","authenticated-orcid":false,"given":"Giorgia","family":"Battipaglia","sequence":"additional","affiliation":[{"name":"16Department of Clinical Medicine and Surgery, Haematology Unit, Federico II University of Naples, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9341-8104","authenticated-orcid":false,"given":"Yves","family":"Chalandon","sequence":"additional","affiliation":[{"name":"17Service d'H\u00e9matologie, D\u00e9partement d'Oncologie, H\u00f4pitaux Universitaires de Gen\u00e8ve, Geneva, Switzerland"},{"name":"18Faculty of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[{"name":"11Practice Harmonisation and Guidelines Committee of European Society for Blood and Marrow Transplantation and Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation, Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-2555","authenticated-orcid":false,"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"19Wessex Genomics Laboratory Service, Salisbury NHS Foundation Trust, Salisbury, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4562-6264","authenticated-orcid":false,"given":"Joanna","family":"Drozd-Sokolowska","sequence":"additional","affiliation":[{"name":"20University Clinical Centre Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-7277","authenticated-orcid":false,"given":"Vaneuza","family":"Funke","sequence":"additional","affiliation":[{"name":"21Blood and Marrow Transplantation Program, Hospital de Cl\u00ednicas, Federal University of Parana, Curitiba, Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[{"name":"22Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"23Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"24Stanford Cancer Institute, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[{"name":"25Center Research and Innovation of Myeloproliferative Neoplasms, Dipartimento di Medicina Sperimentale e Clinic, University of Florence, Azienda Ospedaliero Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[{"name":"26Department of Haematology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[{"name":"27Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[{"name":"28Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-3584","authenticated-orcid":false,"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[{"name":"29Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-438X","authenticated-orcid":false,"given":"Jean Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"8Department of Haematology, King's College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"22Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1460-1611","authenticated-orcid":false,"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[{"name":"1Unit of Bone Marrow Transplantation and Cellular Therapies, Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy"},{"name":"14Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[{"name":"30Hematology and Stem Cell Transplantation and Cellular Therapies Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \"Bianchi-Melacrino-Morelli,\" Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-7972","authenticated-orcid":false,"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"31Wake Forest University School of Medicine, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[{"name":"32Department of Pathology, Texas Tech University Health Sciences Center, El Paso, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[{"name":"33Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"34Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero\u2013Universitaria di Bologna, Istituto di Ematologia \"Ser\u00e0gnoli,\" Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"35Dipartimento di Oncologia ed Onco-Ematologia, Universit\u00e0 Degli Studi di Milano, Milan, Italy"},{"name":"36Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[{"name":"23Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"37Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[{"name":"26Department of Haematology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[{"name":"38Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[{"name":"39Department of Clinical and Experimental Science, University of Brescia, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6539-226X","authenticated-orcid":false,"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[{"name":"40University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"23Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"25Center Research and Innovation of Myeloproliferative Neoplasms, Dipartimento di Medicina Sperimentale e Clinic, University of Florence, Azienda Ospedaliero Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0715-1402","authenticated-orcid":false,"given":"Daniel H.","family":"Wiseman","sequence":"additional","affiliation":[{"name":"41Division of Cancer Sciences, Epigenetics of Haematopoiesis Laboratory, The University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[{"name":"42Practice Harmonisation and Guidelines Committee of the European Society for Blood and Marrow Transplantation Centre Hospitalier Universitaire de Lille, University Lille, INSERM U1286, Infinite, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[{"name":"43European Society for Blood and Marrow Transplantation Chronic Malignancies Working Party, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2025052911212346000_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025052911212346000_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2025052911212346000_bib3","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kr\u00f6ger","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025052911212346000_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41409-024-02437-6","article-title":"Navigating \u201cgrey areas\u201d and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"60","author":"Polverelli","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2025052911212346000_bib5","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41409-023-02094-1","article-title":"Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT","volume":"58","author":"Hern\u00e1ndez-Boluda","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"22","key":"2025052911212346000_bib6","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1182\/blood.2023023476","article-title":"Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee","volume":"143","author":"Onida","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2025052911212346000_bib7","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41409-023-01958-w","article-title":"Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy","volume":"58","author":"Yakoub-Agha","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"2025052911212346000_bib20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjh.18297","article-title":"Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: a combined CIBMTR\/CMWP of EBMT analysis","volume":"198","author":"Dholaria","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2025052911212346000_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bjh.18219","article-title":"Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: a retrospective study by the chronic malignancies working party of the EBMT","volume":"198","author":"McLornan","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2025052911212346000_bib45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjh.16537","article-title":"Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT","volume":"190","author":"McLornan","year":"2020","journal-title":"Br J Haematol"},{"issue":"9","key":"2025052911212346000_bib32","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41375-023-01958-1","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort","volume":"37","author":"Metzgeroth","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"2025052911212346000_bib39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41409-021-01553-x","article-title":"Allogeneic hematopoietic cell transplantation in patients with myeloid\/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT","volume":"57","author":"Hern\u00e1ndez-Boluda","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"2025052911212346000_bib40","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/s41379-021-00817-7","article-title":"Myeloid\/lymphoid neoplasms with FLT3 rearrangement","volume":"34","author":"Tang","year":"2021","journal-title":"Mod Pathol"},{"issue":"5","key":"2025052911212346000_bib53","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14619","article-title":"Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"177","author":"Onida","year":"2017","journal-title":"Br J Haematol"},{"key":"2025052911212346000_bib54","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.leukres.2018.11.003","article-title":"Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan","volume":"75","author":"Itonaga","year":"2018","journal-title":"Leuk Res"},{"issue":"9","key":"2025052911212346000_bib65","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.bbmt.2020.05.013","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic\/myeloproliferative neoplasms-unclassifiable: a retrospective nationwide study of the Japan Society for Hematopoietic Cell Transplantation","volume":"26","author":"Kurosawa","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2025052911212346000_bib8","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.3324\/haematol.2017.183160","article-title":"The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic\/myeloproliferative neoplasms","volume":"103","author":"Meggendorfer","year":"2018","journal-title":"Haematologica"},{"issue":"16","key":"2025052911212346000_bib9","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2025052911212346000_bib10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"key":"2025052911212346000_bib11","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/bcj.2014.94","article-title":"Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia","volume":"5","author":"Lasho","year":"2015","journal-title":"Blood Cancer J"},{"issue":"2","key":"2025052911212346000_bib12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","article-title":"Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients","volume":"34","author":"Mangaonkar","year":"2020","journal-title":"Leukemia"},{"issue":"16","key":"2025052911212346000_bib13","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood.2020007157","article-title":"Toward classifying the unclassifiable","volume":"136","author":"Padron","year":"2020","journal-title":"Blood"},{"issue":"20","key":"2025052911212346000_bib14","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2025052911212346000_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ajh.26481","article-title":"Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management","volume":"97","author":"Szuber","year":"2022","journal-title":"Am J Hematol"},{"issue":"19","key":"2025052911212346000_bib16","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"2025052911212346000_bib17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"2025052911212346000_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2403562","article-title":"WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature","volume":"19","author":"Elliott","year":"2005","journal-title":"Leukemia"},{"issue":"9","key":"2025052911212346000_bib19","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1182\/bloodadvances.2022008204","article-title":"CNL and aCML should be considered as a single entity based on molecular profiles and outcomes","volume":"7","author":"Carre\u00f1o-Tarragona","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2025052911212346000_bib21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3343\/alm.2015.35.3.376","article-title":"T618I-mutated colony stimulating factor 3 receptor in chronic neutrophilic leukemia and chronic myelomonocytic leukemia patients who underwent allogeneic stem cell transplantation","volume":"35","author":"Lee","year":"2015","journal-title":"Ann Lab Med"},{"issue":"7","key":"2025052911212346000_bib22","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1002\/ajh.25811","article-title":"WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): a contemporary series from the Mayo Clinic","volume":"95","author":"Morsia","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"2025052911212346000_bib23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ajh.23193","article-title":"Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation","volume":"87","author":"Helbig","year":"2012","journal-title":"Am J Hematol"},{"issue":"6","key":"2025052911212346000_bib25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2025052911212346000_bib26","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.2023022417","article-title":"How I (diagnose and) treat myeloid \/ lymphoid neoplasms with tyrosine kinase gene fusions","volume":"145","author":"Reiter","year":"2025","journal-title":"Blood"},{"issue":"5","key":"2025052911212346000_bib27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41375-023-01859-3","article-title":"Comprehensive response criteria for myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group","volume":"37","author":"Shomali","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"2025052911212346000_bib28","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients","volume":"95","author":"Rohmer","year":"2020","journal-title":"Am J Hematol"},{"issue":"23","key":"2025052911212346000_bib29","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2025052911212346000_bib30","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2013.129","article-title":"Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid\/lymphoid neoplasms with PDGFR rearrangements in blast phase","volume":"27","author":"Metzgeroth","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"2025052911212346000_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/bloodadvances.2019001111","article-title":"Treatment-free remission in FIP1L1-PDGFRA-positive myeloid\/lymphoid neoplasms with eosinophilia after imatinib discontinuation","volume":"4","author":"Metzgeroth","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2025052911212346000_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/leu.2011.181","article-title":"Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation","volume":"26","author":"Metzgeroth","year":"2012","journal-title":"Leukemia"},{"issue":"20","key":"2025052911212346000_bib34","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood-2017-11-817510","article-title":"PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia","volume":"131","author":"Zhang","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2025052911212346000_bib35","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/leu.2012.8","article-title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases","volume":"26","author":"Lierman","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"2025052911212346000_bib36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025052911212346000_bib37","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25825","article-title":"Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes","volume":"95","author":"Schwaab","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"2025052911212346000_bib38","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/annonc\/mdy173","article-title":"Treatment of the myeloid\/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor","volume":"29","author":"Verstovsek","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"2025052911212346000_bib41","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1002\/ajh.24657","article-title":"Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: comparison with the 2008 version","volume":"92","author":"Iurlo","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"2025052911212346000_bib42","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bjh.17375","article-title":"Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre","volume":"193","author":"Deschamps","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"2025052911212346000_bib43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/bjh.18087","article-title":"How I manage myeloproliferative neoplasm-unclassifiable: practical approaches for 2022 and beyond","volume":"197","author":"McLornan","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2025052911212346000_bib44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ajcp\/aqae033","article-title":"Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study","volume":"162","author":"Crane","year":"2024","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2025052911212346000_bib46","first-page":"103338","article-title":"Diagnostic and management strategies for myeloproliferative neoplasm-unclassifiable (MPN-U): an international survey of contemporary practice","volume":"70","author":"Hargreaves","year":"2022","journal-title":"Curr Res Transl Med"},{"issue":"1","key":"2025052911212346000_bib47","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","article-title":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"10","author":"Polverelli","year":"2023","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025052911212346000_bib48","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/ajh.27321","article-title":"Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management","volume":"99","author":"Szuber","year":"2024","journal-title":"Am J Hematol"},{"issue":"17","key":"2025052911212346000_bib49","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1002\/cncr.33622","article-title":"Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia","volume":"127","author":"Montalban-Bravo","year":"2021","journal-title":"Cancer"},{"issue":"8","key":"2025052911212346000_bib50","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cncr.10832","article-title":"Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia","volume":"95","author":"Onida","year":"2002","journal-title":"Cancer"},{"issue":"6","key":"2025052911212346000_bib51","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"7","key":"2025052911212346000_bib52","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","article-title":"How I treat atypical chronic myeloid leukemia","volume":"129","author":"Gotlib","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2025052911212346000_bib55","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41375-024-02262-2","article-title":"Predicting survival in patients with myelodysplastic\/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"2025052911212346000_bib56","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.24332","article-title":"Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"2025052911212346000_bib57","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/10428194.2016.1217529","article-title":"Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome\/myeloproliferative neoplasm (MDS\/MPN) overlap syndromes","volume":"58","author":"Sharma","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2025052911212346000_bib58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-022-00622-8","article-title":"Myelodysplastic\/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients","volume":"12","author":"Mangaonkar","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025052911212346000_bib59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12907-017-0066-8","article-title":"Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach","volume":"17","author":"Courville","year":"2017","journal-title":"BMC Clin Pathol"},{"issue":"3","key":"2025052911212346000_bib60","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1179\/1607845415Y.0000000028","article-title":"Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: experience of the Argentinean Group of Bone Marrow Transplantation (GATMO)","volume":"21","author":"Basquiera","year":"2016","journal-title":"Hematology"},{"issue":"4","key":"2025052911212346000_bib61","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ajh.25397","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: \"2019 update on diagnosis, risk-stratification, and management.\"","volume":"94","author":"Patnaik","year":"2019","journal-title":"Am J Hematol"},{"issue":"2","key":"2025052911212346000_bib62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","article-title":"Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines","volume":"29","author":"DeFilipp","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2025052911212346000_bib63","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2014.8","article-title":"Myelodysplastic\/myeloproliferative neoplasms, unclassifiable (MDS\/MPN, U): natural history and clinical outcome by treatment strategy","volume":"28","author":"DiNardo","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2025052911212346000_bib64","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.26828","article-title":"Atypical chronic myeloid leukemia and myelodysplastic\/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management","volume":"98","author":"Patnaik","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"2025052911212346000_bib66","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.3324\/haematol.2023.283426","article-title":"Haploidentical donor hematopoietic cell transplantation for myelodysplastic\/myeloproliferative overlap neoplasms: results from a North American collaboration","volume":"108","author":"Jain","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"2025052911212346000_bib67","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"2025052911212346000_bib68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bmt.1705576","article-title":"Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility","volume":"39","author":"Kristt","year":"2007","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"2025052911212346000_bib69","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party","volume":"35","author":"McLornan","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2025052911212346000_bib70","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/hematology.2021000257","article-title":"Allogeneic hematopoietic cell transplantation for older patients","volume":"2021","author":"Lin","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/22\/2561\/2376577\/blood_bld-2024-028000-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/22\/2561\/2376577\/blood_bld-2024-028000-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T15:21:40Z","timestamp":1748532100000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/22\/2561\/536226\/Role-of-allo-HCT-in-nonclassical-MPNs-and-MDS-MPNs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":70,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,5,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024028000","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,29]]},"published":{"date-parts":[[2025,5,29]]}}}